Table 3

Number of events, person years, crude and standardised incidence rates of all cancers other than NMSC and NMSC, in patients with RA treated with JAKis, non-TNFi bDMARDs or TNFi, by time since treatment initiation

EventsPerson years, noCrude incidence rate per 1000 person-yearsStandardised incidence rate per 1000 person-yearsFully adjusted HR*
All cancers other than NMSC
 0–1 year
  JAKi20188410.69.40.96 (0.58 to 1.59)
  Non-TNFi52381513.611.41.11 (0.77 to 1.61)
  TNFi80775910.310.31.0 (Reference)
 1–2 years
  JAKi813585.94.90.67 (0.32 to 1.43)
  Non-TNFi36304911.89.21.25 (0.80 to 1.96)
  TNFi5160008.58.51.0 (Reference)
 2 or more years
  JAKi1075413.212.21.36 (0.67 to 2.75)
  Non-TNFi53418712.710.71.06 (0.74 to 1.53)
  TNFi82736311.111.11.0 (Reference)
 0–1 year
  JAKi24188012.811.21.12 (0.70 to 1.78)
  Non-TNFi40381810.58.30.85 (0.57 to 1.26)
  TNFi7577559.79.71.0 (Reference)
 1–2 years
  JAKi20133814.912.81.48 (0.87 to 2.51)
  Non-TNFi47304115.511.81.43 (0.95 to 2.15)
  TNFi5159918.58.51.0 (Reference)
 2 or more years
  JAKi1573520.418.32.12 (1.15 to 3.89)
  Non-TNFi3941689.47.30.86 (0.57 to 1.31)
  TNFi6373388.68.61.0 (Reference)
  • Non-TNFI includes; rituximab; abatacept; tocilizumab. All HRs estimated from Cox models including an interaction between time since treatment initiation (0–1, 1–2, 2+ years) and treatment exposure cohort. Standardised incidence rate standardised to the age and sex distribution in the TNFi cohort.

  • *Fully adjusted HR: adjusted for age, sex, line of therapy, for comorbidities, SES, disease-related factors and with missing categories included for those variables with missing information.

  • bDMARDs, biological disease-modifying antirheumatic drugs; JAKi, Janus kinase inhibitor; NMSC, non-melanoma skin cancer; RA, rheumatoid arthritis; SES, socioeconomic status; TNFi, tumour necrosis factor inhibitor.